Scientific findings
The Yale team analyzed blood samples from 42 individuals with these post-vaccination symptoms and compared them to 22 people who did not experience such effects. The results revealed immunological abnormalities in patients with PVS, including:
Decrease in certain white blood cells: indicating a possible alteration of the immune response.
Prolonged presence of the SARS-CoV-2 spike protein: this protein, used by the virus to infect cells, was detected in high quantities in some patients, suggesting an unusual persistence in the body.
Reactivation of the Epstein-Barr virus (EBV): responsible in particular for infectious mononucleosis, this latent virus could be reawakened in some patients, suggesting that vaccination could, in rare cases, disrupt the immune balance.
A rare but recognized condition
Although PVS appears to affect a minority of vaccinated individuals, its recognition is essential to ensure appropriate management. Dr. Akiko Iwasaki, an immunologist at Yale, emphasizes the importance of continuing research to better understand this condition and develop effective treatment strategies.
Read more on the next page
